Neuartige Formulierung für Lacosamid
EP4789660
12. August 2026
Anmelder: Shanghai Aucta Pharmaceuticals Co., Ltd. 🇨🇳
Details
- Veröffentlichungs-Nr.
- EP4789660
- Anmeldetag
- 5. Februar 2026
- Veröffentlichung
- 12. August 2026
- Rechtsraum
- EP
Abstract
The patent document discloses a dosage form featuring a unique combination of extended-release and immediate-release components of the active ingredient. This dosage form allows for high drug loading, enabling once-daily administration while providing a sustained window of effective treatment with reduced fluctuations in drug concentration. The document also discloses a method for treating neurological or psychiatric diseases or conditions in a subject.
Anmelder
- Firma
- Shanghai Aucta Pharmaceuticals Co., Ltd.
- Land
- 🇨🇳 China